Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes

scientific article published on 01 August 2006

Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S1470-2045(06)70798-7
P698PubMed publication ID16887488

P2093author name stringThomas Vogt
Michael Landthaler
Albrecht Reichle
Christian Hafner
Brigitte Coras
P2860cites workSubacute cutaneous lupus erythematosus associated with hepatocellular carcinomaQ34222670
Endogenous angiogenesis inhibitorsQ34371061
The anti-angiogenic basis of metronomic chemotherapyQ35788112
PPARgamma as a therapeutic target for tumor angiogenesis and metastasisQ36219139
New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARgamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapyQ36264845
Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcomaQ45095311
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.Q45158856
Activation of PPARγ Specifies a Dendritic Cell Subtype Capable of Enhanced Induction of iNKT Cell ExpansionQ63363446
Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinomaQ79134572
P433issue8
P921main subjectangiogenesis inhibitorQ574834
metastatic prostate carcinomaQ55779807
P304page(s)695-697
P577publication date2006-08-01
P1433published inLancet Oncology CommissionQ13747613
P1476titleAntiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes
P478volume7

Reverse relations

cites work (P2860)
Q40640442Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia
Q42550846Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia
Q59805381Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis
Q37817730Paraneoplastic syndromes in prostate cancer.
Q59793687Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
Q41961938Systems biology: a therapeutic target for tumor therapy

Search more.